How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

Wall Street analysts’ average price target implies 123.4% potential upside for Maze Therapeutics (MAZE), though the article cautions that price targets are a questionable metric. Positive earnings estimate revisions may also support the stock; no share-price move or specific target price is provided.

Analysis

The investable signal is not the target-price gap; it is whether estimate revisions represent a durable change in expected economics or merely updated assumptions around timing and spending. In biotech, a small number of model changes can move estimates without improving the probability-adjusted value of the underlying assets. The key second-order risk is that a revision-led rally raises the cost of future equity financing before clinical or commercial evidence has de-risked the story.

Near term, the stock may respond to continued upward revisions, but that can reverse quickly if revisions narrow or the next company-specific catalyst disappoints. Over 1–3 months, verify revision breadth, the assumptions driving changes, upcoming data/regulatory milestones, and cash runway; none is established by the supplied information. Over 6–18 months, financing needs and clinical execution are likely more consequential than analyst target dispersion. A contrarian possibility is that the very large implied target gap attracts momentum buyers while understating dilution and binary-event risk. No trade is warranted from this signal alone.

Key Decisions for Investors

• Do not treat the target-price upside as a valuation anchor. Before taking exposure to MAZE, verify the number of analysts revising estimates, the direction and size of revisions, and whether changes reflect revenue assumptions, expense timing, or other items.
• Keep MAZE on a catalyst watchlist rather than initiating a position solely on this article. Reassess after reviewing the clinical/regulatory calendar, cash runway, and potential financing requirements.
• If revision breadth persists and no near-term binary event dominates, consider only a small, defined-risk exposure; avoid adding after a sharp sentiment-driven move without confirming the underlying estimate drivers.
• Falsify the positive setup if revisions turn negative, guidance or cash-runway disclosures weaken, or a material clinical/regulatory catalyst fails. No price target or event details are available to set a more precise trigger.